Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells-Reference-Cited by-同舟云学术

Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells

Published:2022-11-25 Issue:1 Volume:107 Page:219-232
ISSN:0175-7598
Container-title:Applied Microbiology and Biotechnology
language:en
Short-container-title:Appl Microbiol Biotechnol

Author:

Tsai Shan-Ko,Hsu Yu-Lin,Chiao Der-Jiang,Shu Pei-Yun,Lin Hui-Tsu,Chang Shu-Fen,Lin Hui-Chung,Huang Shih-Hsin,Wang Chun-Hsiung,Hsiung Chia-Chu,Lin Chang-Chi,Wu Tzong-Yuan,Kuo Szu-Cheng^ORCID

Funder

National Health Research Institutes

Ministry of Science and Technology

Medical Affairs Bureau

Publisher

Springer Science and Business Media LLC

Subject

Applied Microbiology and Biotechnology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s00253-022-12280-8.pdf

Reference53 articles.

1. Akahata W, Nabel GJ (2012) A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J Virol 86(16):8879–8883. https://doi.org/10.1128/jvi.00370-12

2. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 16(3):334–338. https://doi.org/10.1038/nm.2105

3. Arévalo MT, Huang Y, Jones CA, Ross TM (2019) Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice. PLoS Negl Trop Dis 13(4):e0007316. https://doi.org/10.1371/journal.pntd.0007316

4. Barry G, Fragkoudis R, Ferguson MC, Lulla A, Merits A, Kohl A, Fazakerley JK (2010) Semliki forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells. J Virol 84(14):7369–7377. https://doi.org/10.1128/jvi.02310-09

5. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE (2014) Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. The Lancet 384(9959):2046–2052. https://doi.org/10.1016/s0140-6736(14)61185-5

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facile quantitative diagnostic testing for neutralizing antibodies against chikungunya virus;2024-08-27

2. Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions;Frontiers in Microbiology;2024-07-22

3. A safe insect-based Chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques;2024-05-21

4. A tangled threesome: understanding arbovirus infection in Aedes spp. and the effect of the mosquito microbiota;Frontiers in Microbiology;2024-01-03

5. An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope;The Microbe;2023-12